Moderna’s experimental mRNA-based flu vaccine demonstrated a stronger immune response than a currently available standard flu shot in a late-stage phase 3 trial, clearing a path for regulatory ...

Amid promising signs, officials urged caution, noting that the outbreaks vary by clade, response measures, and social ...

Moderna today reported promising relative vaccine efficacy (rVE) findings from a phase 3 trial of its seasonal mRNA flu ...

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial.   In a Phase 3 study, the ...

An influenza vaccine candidate from Moderna showed promising results in a late-stage trial, bringing the drug maker one step ...

Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...

Moderna's mRNA flu vaccine showed 26.6% better efficacy than a standard flu shot in adults 50 and older during a global Phase ...

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

Vaccine maker Moderna, Inc. (MRNA) said on Monday that its experimental seasonal flu vaccine demonstrated strong effectiveness in a late-stage study as compared to a currently available standard-dose ...

If we don’t invest in technologies like mRNA vaccines for pandemic influenza now, once a virus starts going human-to-human, ...

The administration in May canceled a contract awarded to Moderna for the late-stage development of its bird flu vaccine for humans. When asked about the uncertain regulatory environment in the U.S., ...